Business Wire

NY-KP-SANGHVI

23.8.2021 12:02:05 CEST | Business Wire | Press release

Share
KP Sanghvi Announces Serena Williams Jewelry Collection Now Available to New Global Markets

KP Sanghvi, the global licensee for Serena Williams Jewelry, is pleased to announce the international expansion of its Serena Williams Jewelry collection. Building upon its introduction in the United States this month, the brand will be vetting new global opportunities in additional markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210823005058/en/

Gautam Begani, COO of KP Sanghvi Jewelry stated, “It has been an absolute joy working with Serena and watching her inspire new fine jewelry collections that mirror her bold, yet playful, sense of style. We’re so excited about our new retail distribution with one of the largest specialty jewelers in the US. Our major next step is taking Serena’s diamond jewelry designs to a wider audience of her fans globally.”

Serena Williams added, “I love expressing myself through fashion. My diamond jewelry collection is a beautiful celebration of the strong women in my life and around the world. I’m so grateful for the opportunity for my designs to inspire people to love themselves, believe in themselves, and to bring a little sparkle and joy to special moments.”

The SWJ Collection focuses on three key design themes:

Unstoppable : Inspiring strength and resilience. This collection reflects Serena’s positive outlook on life, her determination, and the unstoppable resilience she embodies.

Believe, Be Great : Self-empowerment and individual expression. A reflection of Serena’s persona and the importance of believing in oneself to achieve one’s goals through words of affirmation like “queen ,” “great,” “inspire,” and “loved .”

By My Side : A celebration of mothers, daughters, aunties, and grandmothers, and the love we share... inspired by Serena and her daughter.

Serena Williams Jewelry includes over 60 sparkling rings, necklaces, earrings, and bracelets set in gold and sterling silver accented with brilliant, natural diamonds. Prices range from $99 to $999 USD depending on the metal and carat weight.

View the entire collection at www.serenawilliamsjewelry.com and read more at https://www.jckonline.com/editorial-article/zales-serena-williams-jewelry/

ABOUT K.P. SANGHVI AND SERENA WILLIAMS JEWELRY

Under the personal design guidance and oversight of Serena Williams, all Serena Williams Jewelry is expertly crafted by KP Sanghvi, one of the largest vertically integrated diamond companies in the world. As the worldwide licensee of the SWJ brand and with over 50 years of experience working with jewelry brands across the globe, the Sanghvi family places social responsibility at the forefront of their company values, along with integrity and quality craftsmanship.

Link:

ClickThru

Social Media:

https://www.facebook.com/serenawilliamsjewelry

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye